AuthorsWardley, Andrew M
Canon, J. L.
Peña Murillo, C.
Badovinac Crnjevic, T.
AffiliationNIHR Manchester Clinical Research Facility at The Christie and Division of Cancer Sciences and University of Manchester, Manchester Academic Health Science Centre, Mancheste
MetadataShow full item record
AbstractTreatment of patients with cancer in hospitals or clinics is resource-intensive and imposes a burden on patients. 'Flexible care' is a term that can be used to describe treatment administered outside the oncology ward, oncological outpatient clinic or office-based oncologist setting. Programmes that reduce travel burden by bringing cancer treatment to the patient's home, workplace or closer to the patient's home, in the form of satellite clinics or mobile cancer units, expand treatment capacity and are well received. Clinical trial data show that, compared with intravenous administration, subcutaneous (s.c.) administration of trastuzumab is preferred by patients with breast cancer (BC), saves healthcare professionals' (HCPs) time, reduces drug preparation and administration time and reduces direct and indirect costs. As such, s.c. trastuzumab is well suited to flexible care. The results of a Belgian study (BELIS) show that home administration of s.c. trastuzumab is feasible and preferred by patients with BC. Numerous programmes and pilot studies in Europe show that s.c. trastuzumab can be administered effectively in the patient's home, in primary care settings or local hospitals. Such programmes require planning, training, careful patient selection and technology to link patients, caregivers and specialists in oncology clinics. Once these elements are in place, flexible care offers patients with BC a choice of how treatment may be delivered and lead to improved quality of life, while reducing pressure on HCPs and hospitals. The concept of flexible care is particularly relevant amid the COVID-19 pandemic where guidelines have been developed encouraging remote care.
CitationWardley A, Canon JL, Elsten L, Pena Murillo C, Badovinac Crnjevic T, Fredriksson J, et al. Flexible care in breast cancer. ESMO Open. 2021;6(1):100007.
- Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer.
- Authors: Denys H, Martinez-Mena CL, Martens MT, D'Hondt RG, Graas ML, Evron E, Fried G, Ben-Baruch NE, Vulsteke C, Van Steenberghe MM
- Issue date: 2020 May
- COVID-19 outbreak: An experience to reappraise the role of hospital at home in the anti-cancer drug injection.
- Authors: Mittaine-Marzac B, Zogo A, Crusson JC, Cheneau V, Pinel MC, Brandely-Piat ML, Amrani F, Havard L, Balladur E, Louissaint T, Nivet L, Ankri J, Aegerter P, De Stampa M
- Issue date: 2021 Apr
- Hospital-based or home-based administration of oncology drugs? A micro-costing study comparing healthcare and societal costs of hospital-based and home-based subcutaneous administration of trastuzumab.
- Authors: Franken M, Kanters T, Coenen J, de Jong P, Jager A, Groot CU
- Issue date: 2020 Aug
- Subcutaneous trastuzumab (Herceptin) versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: A time, motion and cost assessment study in a lean operating day care oncology unit.
- Authors: Tjalma WAA, Van den Mooter T, Mertens T, Bastiaens V, Huizing MT, Papadimitriou K
- Issue date: 2018 Feb
- Challenges of Cancer Immunotherapy during the COVID-19 Pandemic.
- Authors: Kuderer NM, Lyman GH
- Issue date: 2021 Feb